Wall Street analysts expect Zynerba Pharmaceuticals Inc (NASDAQ:ZYNE) to announce earnings per share of ($0.69) for the current fiscal quarter, Zacks reports. Zero analysts have issued estimates for Zynerba Pharmaceuticals’ earnings. Zynerba Pharmaceuticals reported earnings per share of ($0.63) in the same quarter last year, which would suggest a negative year over year growth rate of 9.5%. The company is expected to announce its next earnings results on Tuesday, November 13th.

According to Zacks, analysts expect that Zynerba Pharmaceuticals will report full-year earnings of ($3.13) per share for the current fiscal year, with EPS estimates ranging from ($3.18) to ($3.06). For the next fiscal year, analysts forecast that the business will post earnings of ($2.61) per share, with EPS estimates ranging from ($2.68) to ($2.57). Zacks Investment Research’s earnings per share averages are a mean average based on a survey of research firms that that provide coverage for Zynerba Pharmaceuticals.

Zynerba Pharmaceuticals (NASDAQ:ZYNE) last posted its earnings results on Thursday, August 2nd. The company reported ($0.89) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.77) by ($0.12).

Several research firms recently weighed in on ZYNE. Cantor Fitzgerald restated a “buy” rating and issued a $21.00 target price on shares of Zynerba Pharmaceuticals in a report on Tuesday, October 2nd. Zacks Investment Research lowered Zynerba Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Saturday, September 22nd. ValuEngine upgraded Zynerba Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Tuesday, August 14th. HC Wainwright set a $23.00 target price on Zynerba Pharmaceuticals and gave the stock a “buy” rating in a report on Monday, August 6th. Finally, Canaccord Genuity reduced their target price on Zynerba Pharmaceuticals from $18.00 to $15.00 and set a “buy” rating for the company in a report on Friday, August 3rd. One analyst has rated the stock with a sell rating, two have given a hold rating and five have assigned a buy rating to the company’s stock. The company presently has an average rating of “Buy” and a consensus target price of $18.93.

ZYNE traded up $0.44 on Tuesday, hitting $7.63. The company had a trading volume of 15,734 shares, compared to its average volume of 406,728. Zynerba Pharmaceuticals has a 1-year low of $5.59 and a 1-year high of $15.14. The firm has a market cap of $143.81 million, a P/E ratio of -3.11 and a beta of 4.52.

In other Zynerba Pharmaceuticals news, Director John P. Butler purchased 5,000 shares of the company’s stock in a transaction on Wednesday, August 22nd. The shares were bought at an average cost of $6.43 per share, with a total value of $32,150.00. Following the transaction, the director now directly owns 5,000 shares in the company, valued at approximately $32,150. The purchase was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, CFO James E. Fickenscher purchased 8,518 shares of the company’s stock in a transaction on Monday, August 6th. The stock was acquired at an average cost of $5.97 per share, for a total transaction of $50,852.46. Following the completion of the transaction, the chief financial officer now owns 20,718 shares in the company, valued at $123,686.46. The disclosure for this purchase can be found here. Over the last 90 days, insiders purchased 32,318 shares of company stock valued at $194,404. Corporate insiders own 12.67% of the company’s stock.

A number of hedge funds and other institutional investors have recently modified their holdings of ZYNE. Millennium Management LLC increased its position in Zynerba Pharmaceuticals by 116.0% in the 2nd quarter. Millennium Management LLC now owns 224,511 shares of the company’s stock worth $2,187,000 after buying an additional 120,570 shares during the period. Paloma Partners Management Co bought a new stake in shares of Zynerba Pharmaceuticals during the second quarter valued at approximately $493,000. BlackRock Inc. increased its position in shares of Zynerba Pharmaceuticals by 5.4% during the first quarter. BlackRock Inc. now owns 715,185 shares of the company’s stock valued at $6,216,000 after purchasing an additional 36,488 shares during the period. LMR Partners LLP bought a new stake in shares of Zynerba Pharmaceuticals during the second quarter valued at approximately $312,000. Finally, Pennsylvania Trust Co increased its position in shares of Zynerba Pharmaceuticals by 17.4% during the third quarter. Pennsylvania Trust Co now owns 202,100 shares of the company’s stock valued at $1,649,000 after purchasing an additional 30,000 shares during the period. 14.22% of the stock is currently owned by institutional investors.

Zynerba Pharmaceuticals Company Profile

Zynerba Pharmaceuticals, Inc operates as a clinical stage specialty pharmaceutical company. The company focuses on developing and commercializing pharmaceutically-produced transdermal cannabinoid treatments for rare or near-rare neuropsychiatric disorders. Its product candidates include ZYN002, which completed Phase II clinical trial for pediatric and adolescent patients with fragile X syndrome, pediatric and adolescent patients with developmental and epileptic encephalopathies, and adult patients with refractory epileptic focal seizures; and ZYN001 that is in Phase I clinical trial to treat Tourette syndrome.

Further Reading: What is Considered a Good Return on Equity (ROE)?

Get a free copy of the Zacks research report on Zynerba Pharmaceuticals (ZYNE)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Zynerba Pharmaceuticals (NASDAQ:ZYNE)

Receive News & Ratings for Zynerba Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zynerba Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.